Study Groups

WWARN facilitates a number of collaborative Study Groups to undertake individual patient data meta-analyses to answer specific research questions about malaria treatments and antimalarial drug resistance. Gathering and combining data sets from multiple studies increases sample sizes, so that effects, including smaller effects, and effects on sub-populations can be identified with greater certainty. Working together and combining data from different regions and populations is improving our understanding of drug resistance and strengthening global efforts to control and eventually eliminate malaria.

clinic_in_bamako
i
Dominic Chavez World Bank
lymphocyte with rbcs
Determining what affects White Blood Cell (WBC) count at baseline and during acute phase of malaria infection.  
Baseline information on parasitological response to ACTs in AsiaA pooled analysis to assess the baseline early parasitological response after artemisi...

Baseline information on parasitological response to ACTs in Asia

A pooled analysis to assess the baseline early parasitological response after artemisinin combination therapy (ACT) treatment in Asia. The analysis compiles the day 3 parasite positivity rates (PPR) in patients with uncomplicated Plasmodium falciparum malaria enrolled in ACT clinical efficacy trials conducted in Asia.

Data gathering and curation has started. Data meeting the inclusion criteria has already been collected and standardised from over 12,000 patients. Data analysis will start April 2015 with a manuscript schedules for submission and publication by December 2015. 

show more
This is an extension of the WWARN Haemoglobin-Haematocrit Relationship in Malaria Study Group and the Antimalarial–Antiretroviral Analy...

This is an extension of the WWARN Haemoglobin-Haematocrit Relationship in Malaria Study Group and the Antimalarial–Antiretroviral Analyses Study Group. These groups aimed to consider the effect of HIV disease and co-administration of widely-used antiretroviral drugs (ARVs) on artemisinin-based combination therapies (ACTs).  

show more
The Dihydroartemisinin-Piperaquine for Intermittent Preventive Treatment in Pregnancy Study Group aims to determine the safety and efficacy of intermi...

The Dihydroartemisinin-Piperaquine for Intermittent Preventive Treatment in Pregnancy Study Group aims to determine the safety and efficacy of intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) compared to IPTp with sulfadoxine-pyrimethamine (SP), for the prevention of malaria and adverse birth outcomes among pregnant women in sub-Saharan Africa.

show more
woman with child in Sierra Leone
The Study Group was formed in January 2024 to update and expand the WWARN work of the K13 Genotype-Phenotype Study Group, which was published in BMC M...

The Study Group was formed in January 2024 to update and expand the WWARN work of the K13 Genotype-Phenotype Study Group, which was published in BMC Medicine.

show more
Pooled analyses of the efficacy and safety of single low-dose primaquine to interrupt P. falciparum malaria transmission.Data collection has closed an...

Pooled analyses of the efficacy and safety of single low-dose primaquine to interrupt P. falciparum malaria transmission.

Data collection has closed and curation is ongoing. Analysis and draft publications are planned for circulation to the Group by the June of 2017.

show more
Analysis of haematological response before and after antimalarial treatment. A pooled analysis to understand the normal haematological response a...

Analysis of haematological response before and after antimalarial treatment. 

A pooled analysis to understand the normal haematological response and recovery following the treatment of uncomplicated malaria. The group will work together to quantify the risks and benefits of different treatment options of both ACTs and other antimalarials.

Data meeting the inclusion criteria has been collected and standardised from over 70,000 patients. Data gathering, curation and data analysis have been completed. A manuscript is under review of study group members and expected to be submitted for publication Q2 2020. 

show more
The First Trimester Safety of ACTs Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use of arte...

The First Trimester Safety of ACTs Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use of artemisinin combination therapies in the first trimester of pregnancy.

show more
An analysis of pooled individual patient data to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on lumefantr...

An analysis of pooled individual patient data to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on lumefantrine pharmacokinetics (and pharmacodynamics).

This study group has just opened for data collection. If you have any data you would like to share, or if you would like to participate in the project, please contact pharmacology@wwarn.org.

show more
people
The Piperaquine Safety Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use and optimal dosing ...

The Piperaquine Safety Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use and optimal dosing of dihydroartemisinin-piperaquine in all key target populations.

The study group call for contributors opened in June 2016 with a first scoping meeting held in July. Data collection is planned to close by end of 2016, with analysis due in 2018-2019.

show more
Doctor treating baby who is held by father
Analysis of how age impacts the effect of primaquine dose on gastrointestinal tolerability in patients with Plasmodium vivax and Plasmodium ovale mala...

Analysis of how age impacts the effect of primaquine dose on gastrointestinal tolerability in patients with Plasmodium vivax and Plasmodium ovale malaria

show more
The Sulphadoxine-Pyrimethamine (SP) resistance Study Group’s aim is to provide open access to, and establish maps with, the most recent data on SP res...

The Sulphadoxine-Pyrimethamine (SP) resistance Study Group’s aim is to provide open access to, and establish maps with, the most recent data on SP resistance to inform policy decisions on the clinical effectiveness of SP when provided as part of intermittent preventive treatment of malaria in pregnancy (IPTp) or seasonal malaria chemoprevention (SMC).

show more
The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of mala...

The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of malaria in pregnancy including intermittent preventive therapy (IPTp) with dihydroartemisinin-piperaquine (DP) and intermittent screening and treatment (ISTp) with DP or artemether-lumefantrine (AL).

show more
The sulphadoxine-pyrimethamine (SP) resistance Data Access Group’s aim is to provide maps and open access to the most recent data on molecular markers...

The sulphadoxine-pyrimethamine (SP) resistance Data Access Group’s aim is to provide maps and open access to the most recent data on molecular markers of SP resistance to help policy makers make informed decisions with regard to use of SP for intermittent preventive treatment of malaria in pregnancy (IPTp) or seasonal malaria chemoprevention (SMC).

show more
The paediatric single low-dose (SLD) primaquine safety study group aims to describe and compare the safety of SLD primaquine for transmission blocking...

The paediatric single low-dose (SLD) primaquine safety study group aims to describe and compare the safety of SLD primaquine for transmission blocking of Plasmodium falciparum in young children (under 5 years of age) with that in older children and adults.

show more
Sub-study groups include the Artemether-Lumefantrine / ARV PK Study Group and the ACT-ARV Safety Study Group.
A pooled analysis of methaemoglobin as a marker of primaquine antihypnozoite activity in Plasmodium vivax malaria
Development of statistical methods to infer the relationship between the percentage of resistant infections, parasite clearance half-life and the prop...

Development of statistical methods to infer the relationship between the percentage of resistant infections, parasite clearance half-life and the proportion of treated individuals still positive on days one, two and three of treatment

show more